While StockTwits is rarely any better than iHub, Y
Post# of 144633
![](/assets/46931549/no_avatar_available_thumb.jpg)
I take some solace in that it appears she left the FDA in 2022. So hopefully someone else was assigned to Cytodyn since then and has a far better understanding of Leronlimab. At minimum, I hope whoever that person is doesn't do their "research" on iHub like Strayhorn did. Unreal.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)